CHCWM – Cancer & Hematology Centers of West Michigan

ALKS 4230-003 (Alkermes Inc. )

ALKS 4230-003 (Alkermes Inc. ) Description:  Clinical and Immunologic Activity of Nemvaleukin Alfa With a less Frequent IV Dosing With Pembrolizumab and Impact on Tumor Microenvironment in Soloid Tumor Patients (Artistry-3) Mechanism of Action:  IL2 receptor agonist Target Patient Population: Cutaneous melanoma, Renal Cell, Triple Negative Breast, MMS Colorectal, Ovarian and any MSI-High solid tumors

AstraZeneca D9268C00001 (TROPION-Breast01)

  A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) PI: Amy VanderWoude Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint

AstraZeneca SERENA-6

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor (SERENA-6) Principal Investigator:

Genentech (CELESTIMO)

  PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY PI: Dr. Brinker

eFT226-0002 (Effector Therapeutics)

eFT226-0002 (Effector Therapeutics) Description:  A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies Mechanism of Action:  eFT226 is a potent and selective inhibitor of translation of select mRNAs Target Population:  .  ER positive breast cancer with FGFR amplifications, and NSCLC with KRAS G12C mutations (in

GENMAB (GCT1046-04)

GENMAB (GCT1046-04) A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at

C4161001 (Pfizer)

Description:  Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy. Mechanism of Action:  CDK2 inhibitor Target Patient Population:   Small cell Lung Cancer, Platinum Resistant Ovarian, Non-small cell Lung Cancer; in combination with palbociclib and fulvestrant for HR+ HER2-

C4391001 ( Pfizer)

Description:  A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors. Mechanism of Action:  CDK4 inhibitor Target Patient Population:   Metastatic Breast Cancer, NSCLC (adeno), Prostate cancer, Colorectal cancer, Liposarcoma and tumor types with CDK4

C4391002  (Pfizer)

Description:  Phase 1B/2, Open Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in participants with Advanced Solid Tumor Mechanism of Action:  CDK2 inhibitor + CDK4 inhibitor Target Patient Population:   All solid tumors, but is especially attractive

SGN B7H4V-001 (Seagen, Inc.)

Description:  A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors Mechanism of Action:  .antibody drug conjugate to B7H4V.  B7H4 is an immune checkpoint protein present on cancer cells Target Patient Population:  Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers. Study Design:  Drug